Similar articles

• Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

  Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Stevenson M, et al. Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Health Technol Assess. 2009. PMID: 19846028 Review.
• Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.

  Seaman CD, Smith KJ, Ragni MV. Seaman CD, et al. Thromb Res. 2013;132(6):647-51. doi: 10.1016/j.thromres.2013.09.015. Epub 2013 Sep 20. Thromb Res. 2013. PMID: 24139508
• Letter to the Editor "Gender related aspects of bleeding with rivaroxaban in venous thromboembolism - Potential for pitfalls": A comment to "Impact of gender on safety and efficacy of rivaroxaban in adolescents & young adults with venous thromboembolism" by Manuela Krause et al. (Thrombosis Research 2016, published online).

  Beyer-Westendorf J. Beyer-Westendorf J. Thromb Res. 2016 Dec;148:152-153. doi: 10.1016/j.thromres.2016.10.021. Epub 2016 Oct 26. Thromb Res. 2016. PMID: 28029382 No abstract available.
• Rivaroxaban: future in anticoagulation practice?

  Paramanathan V. Paramanathan V. Hematology. 2008 Oct;13(5):257-60. doi: 10.1179/102453308X343473. Hematology. 2008. PMID: 18854086 Review.
• [New oral anticoagulants in the treatment of venous thromboembolism].

  Bertoletti L, Lega JC, Moulin N, Buchmuller A, Mismetti P, Decousus H. Bertoletti L, et al. Presse Med. 2013 Sep;42(9 Pt 1):1232-8. doi: 10.1016/j.lpm.2013.06.001. Epub 2013 Jul 19. Presse Med. 2013. PMID: 23876652 French.